Risk of hyperkalemia in patients with type 2 diabetes mellitus prescribed with SGLT2 versus DPP-4 inhibitors.

Mei Zhen WuTiew-Hwa Katherine TengChristopher Tze-Wei TsangYap-Hang ChanChi-Ho LeeQing-Wen RenJia-Yi HuangIok-Fai CheangYi-Kei TseXin-Li LiXin XuHung-Fat TseCarolyn Su Ping LamKai-Hang Yiu

Published in: European heart journal. Cardiovascular pharmacotherapy (2023)

Our study provides real-world evidence that compared with DPP-4 inhibitors, SGLT2 inhibitors were associated with lower risk of hyperkalemia, and did not increase the incidence of hypokalemia in patients with T2DM.

Keyphrases

type diabetes
adipose tissue
metabolic syndrome
skeletal muscle
insulin resistance